Neutralization of IFN-? reverts clinical and laboratory features in a mouse model of macrophage activation syndrome - 05/04/18
, Ivan Caiello, BS a, Antonia Pascarella, PhD a, Alexei A. Grom, MD b, Claudia Bracaglia, MD a, Laurence Chatel, DUT c, Walter G. Ferlin, PhD c, Emiliano Marasco, MD a, Raffaele Strippoli, MD, PhD d, Cristina de Min, MD c, Fabrizio De Benedetti, MD, PhD aAbstract |
Background |
The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a large body of evidence supports the involvement of mechanisms similar to those implicated in the setting of primary hemophagocytic lymphohistiocytosis.
Objective |
We sought to investigate the pathogenic role of IFN-γ and the therapeutic efficacy of IFN-γ neutralization in an animal model of MAS.
Methods |
We used an MAS model established in mice transgenic for human IL-6 (IL-6TG mice) challenged with LPS (MAS mice). Levels of IFN-γ and IFN-γ–inducible chemokines were evaluated by using real-time PCR in the liver and spleen and by means of ELISA in plasma. IFN-γ neutralization was achieved by using the anti–IFN-γ antibody XMG1.2 in vivo.
Results |
Mice with MAS showed a significant upregulation of the IFN-γ pathway, as demonstrated by increased mRNA levels of Ifng and higher levels of phospho–signal transducer and activator of transcription 1 in the liver and spleen and increased expression of the IFN-γ–inducible chemokines Cxcl9 and Cxcl10 in the liver and spleen, as well as in plasma. A marked increase in Il12a and Il12b expression was also found in livers and spleens of mice with MAS. In addition, mice with MAS had a significant increase in numbers of liver CD68+ macrophages. Mice with MAS treated with an anti–IFN-γ antibody showed a significant improvement in survival and body weight recovery associated with a significant amelioration of ferritin, fibrinogen, and alanine aminotransferase levels. In mice with MAS, treatment with the anti–IFN-γ antibody significantly decreased circulating levels of CXCL9, CXCL10, and downstream proinflammatory cytokines. The decrease in CXCL9 and CXCL10 levels paralleled the decrease in serum levels of proinflammatory cytokines and ferritin.
Conclusion |
These results provide evidence for a pathogenic role of IFN-γ in the setting of MAS.
Le texte complet de cet article est disponible en PDF.Key words : Macrophage activation syndrome, hemophagocytic lymphohistiocytosis, IFN-γ
Abbreviations used : ALT, HLH, MAS, pHLH, sJIA, STAT1, WT
Plan
| Supported by the Italian Ministry of Health (Rome, Italy) Young Investigator Grants (GR-2011-02347874; to G.P.), by the FP7 Grant FIGHT-HLH (agreement no. 306124; to F.D.B. and C.d.M.), and by National Institutes of Health grant R01-AR059049 (to A.A.G.). |
|
| Disclosure of potential conflict of interest: G. Prencipe receives grant support from Young Investigator Grants (GR-2011-02347874). A. A. Grom receives grant support from the National Institutes of Health (R01-AR0590490); serves as a consultant for Novartis, Novimmne, and Juno; receives payment for lectures from Novartis; and receives royalties from UpToDate. C. de Min receives grant support from FP7 grant FIGHT-HLH. F. De Benedetti receives grant support from Grant FIGHT-HLH. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 4
P. 1439-1449 - avril 2018 Retour au numéro
Article précédent
- Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1)
- Desirée Schubert, Marie-Christine Klein, Sarah Hassdenteufel, Andrés Caballero-Oteyza, Linlin Yang, Michele Proietti, Alla Bulashevska, Janine Kemming, Johannes Kühn, Sandra Winzer, Stephan Rusch, Manfred Fliegauf, Alejandro A. Schäffer, Stefan Pfeffer, Roger Geiger, Adolfo Cavalié, Hongzhi Cao, Fang Yang, Yong Li, Marta Rizzi, Hermann Eibel, Robin Kobbe, Amy L. Marks, Brian P. Peppers, Robert W. Hostoffer, Jennifer M. Puck, Richard Zimmermann, Bodo Grimbacher
- Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency
- Hassan Abolhassani, Janet Chou, Wayne Bainter, Craig D. Platt, Mahmood Tavassoli, Tooba Momen, Marzieh Tavakol, Mohammad Hossein Eslamian, Mohammad Gharagozlou, Masoud Movahedi, Mohsen Ghadami, Amir Ali Hamidieh, Gholamreza Azizi, Reza Yazdani, Mohsen Afarideh, Alireza Ghajar, Arash Havaei, Zahra Chavoshzadeh, Seyed Alireza Mahdaviani, Taher Cheraghi, Nasrin Behniafard, Reza Amin, Soheila Aleyasin, Reza Faridhosseini, Farahzad Jabbari-Azad, Mohammamd Nabavi, Mohammad Hassan Bemanian, Saba Arshi, Rasol Molatefi, Roya Sherkat, Mahboubeh Mansouri, Mehrnaz Mesdaghi, Delara Babaie, Iraj Mohammadzadeh, Javad Ghaffari, Alireza Shafiei, Najmeddin Kalantari, Hamid Ahanchian, Maryam Khoshkhui, Habib Soheili, Abbas Dabbaghzadeh, Afshin Shirkani, Rasoul Nasiri Kalmarzi, Seyed Hamidreza Mortazavi, Javad Tafaroji, Abbas Khalili, Javad Mohammadi, Babak Negahdari, Mohammad-Taghi Joghataei, Basel K. al-Ramadi, Capucine Picard, Nima Parvaneh, Nima Rezaei, Talal A. Chatila, Michel J. Massaad, Sevgi Keles, Lennart Hammarström, Raif S. Geha, Asghar Aghamohammadi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?